Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study
Sarah P. Blagden(Churchill Hospital), Elizabeth Ruth Plummer, Elisabeth Oelmann(Nucana (United Kingdom)), Mustafa Elshani(University of St Andrews), Fiona G. McKissock(Nucana (United Kingdom)), Stefan N. Symeonides(Edinburgh Cancer Research), Alison L. Dickson(University of St Andrews), David J. Harrison(NHS Lothian), Natalie Cook(Manchester Academic Health Science Centre), Zhuang Boh(Edinburgh Cancer Research), Ying Zhang(Sun Yat-sen University), TR Jeffry Evans(Beatson West of Scotland Cancer Centre), Noor Md Haris(Freeman Hospital), Aglaia Skolariki(MRC Clinical Trials Unit at UCL), Jeffrey D. Bloss(Nucana (United Kingdom)), In Hwa Um(University of St Andrews)
Cited by 1
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
High-frequency developmental abnormalities in p53-deficient mice
|Current Biology|1995|467